Table 1.

Key trials of imatinib in advanced c-KIT-positive gastrointestinal stromal tumors.

Reference	Imatinib		Response (%)			Outcomes
	dose (mg)	N	OR	SD	PD	PFS	OS
EORTC phase I dose escalation study
Van Oosterom et al. [2002]	400–1000	35	54	37	5	80% @ 9 months	NR
EORTC phase II
Verweij et al. [2003]	800	27	71	18	11	73% @ 12 months	NR
US–Finland B2222 phase II
Blanke et al. [2008a]	400	73	69	14	15	20 months median	57 months median
	600	74	68	18	8	26 months median	57 months median
						p = 0.37	p = 0.55
Japanese B1201 phase II
Nishida et al. [2008b]	400	28	61	39	0	74.1 weeks median	74% @ 3 years
	600	46	74	17	4	107.3 weeks median
						p = 0.19
EORTC-AGITG-ISG 62005 phase III
Verweij et al. [2004]	400	473	50	32	13	31% @ 3 years	58% @ 3 years
	800	473	54	32	9	35% @ 3 years	60% @ 3 years
						p = 0.12	p = 0.59
US–Canadian Intergroup S0033 phase III
Blanke et al. [2008b]	400	345	45	25	12	29% @ 3 years	64% @ 3 years
	800	349	45	22	10	33% @ 3 years	62% @ 3 years
						p = 0.13	p = 0.58

AGITG, Australasian Gastrointestinal Trials Group; EORTC, European Organisation for Research and Treatment of Cancer; ISG, Italian Sarcoma Group; OR, objective response; NR, not reported; OS, overall survival; PD, progressive disease; PFS, progression-free survival; SD, stable disease.